Researchers at the University of Pennsylvania have found a way to coat small drug-delivery vehicles and other foreign objects with a synthetic "passport" peptide that fools the immune system into allowing the objects to survive longer in the human body.
When it comes to drug delivery, it's hard these days to overlook the buzzing field of nanoengineering. Highly targeted nanoparticles are on the cutting edge of the growing field, and according to BIND Biosciences' Jeff Hrkach, there are big things in store for the tiny drug carriers.
Researchers at Barcelona's Vall d'Hebron Institute of Oncology in Spain and U.S. biotech Alnylam Pharmaceuticals have shown that, with a novel delivery technique, they can actively "silence" cancer genes with molecules using the selective interference technique, RNAi.
Call it the Trojan horse of nanomedicine: Researchers have developed a way to cloak drug-carrying nanoparticles with the same membranes as the body's own white blood cells, allowing those drugs to bypass the immune system without being harmed.
Researchers at the Indian Institute of Technology Kharagpur have created nanoparticles out of silk fibers that can deliver drugs to specific targets when combined with other proteins.
Researchers in Switzerland have created a novel drug delivery system using nanosized magnets to deliver toxic drugs to specific parts of a patient's body. The triggered delivery is a step toward creating "intelligent" drugs with highly targeted functions.
Researchers at the University of Texas at Arlington and UT Southwestern Medical Center are developing a drug delivery system that uses nanoparticles to bring regenerative drugs into the lungs.
The combination of Celgene's Abraxane with gemcitabine has improved survival in advanced pancreatic cancer by almost two months, but this isn't as much as some doctors were hoping for, according to a report in The New York Times .
If Northwestern Medicine's mouse studies come good, then in the future, doctors could treat lymphoma without toxic drugs with something as simple as minute particles of gold. These block the entry of HDL cholesterol and starve the cancer cells to death, according to new research in PNAS .
Israeli company Quiet Therapeutics has captured funding of $5.5 million to develop its nanoparticle-based delivery system for RNAi and small-molecule drugs for cancer and inflammation.